Effects of Lithium on Suicide Prevention in Adolescents and Young Adults With Bipolar Disorder in China
Investigating the Effects of Lithium Carbonate on Suicide and Self-harm in Adolescents and Young Adults With Bipolar Disorder in China
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Xin Yu
- Phone Number: 86-10-82801999
- Email: yuxin@bjmu.edu.cn
Study Contact Backup
- Name: Ni Xu
- Email: nixu@bjmu.edu.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100191
- Recruiting
- Mental Health Institute of Peking University
-
Contact:
- Xin Yu, Professor
- Phone Number: 86-10-82801999
- Email: yuxin@bjmu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
-
1 For Lithium group
- Aged 12-45 years (adolescents 12-17, young adults 18-45).
- Diagnosed with bipolar disorder using the the Mini-International Neuropsychiatric Interview (M.I.N.I.) (M.I.N.I.; version 5.0) based on Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria.
- Adolescents diagnosed using the M.I.N.I. Kid version.
- Lithium medication adherence of at least 80% in the first six months over the past year.
- Not in an acute phase of illness.
- Patient or guardian able to participate in assessment interviews.
- Informed consent signed by participants and guardians (for adolescents).
2 for Non-lithium group
- Aged 12-45 years (adolescents 12-17, young adults 18-45).
- Diagnosed with bipolar disorder using the Mini-International Neuropsychiatric Interview (M.I.N.I.; version 5.0) based on DSM-IV criteria.
- Adolescents diagnosed using the M.I.N.I. Kid version.
- No lithium use over the past year.
- Not in an acute phase of illness.
- Patient or guardian able to participate in assessment interviews.
- Informed consent signed by participants and guardians (for adolescents).
Exclusion Criteria:
- Severe physical illness or active substance abuse.
- Severe cognitive impairments, including developmental delays or dementia.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Lithium Group
|
Participants must have been prescribed lithium for the past year and demonstrate at least 80% adherence to their lithium medication regimen during the first six months of the study period.
|
|
Non-lithium Group
|
No history of lithium use within the past year
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Suicidal ideation
Time Frame: over the past year
|
Measured using the Columbia Suicide Severity Rating Scale (C-SSRS)
|
over the past year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Suicidal attempt
Time Frame: over the past year
|
measured using the Columbia Suicide Severity Rating Scale (C-SSRS)
|
over the past year
|
|
Non-suicidal self-injury
Time Frame: over the past year
|
over the past year
|
|
|
Violent and aggressive behaviors
Time Frame: over the past year
|
measured using the Chinese version of the Buss & Perry Aggression Questionnaire
|
over the past year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depressive symptoms
Time Frame: over the past two weeks
|
measured by Beck Depression Inventory
|
over the past two weeks
|
|
Mood symptoms
Time Frame: over the past year
|
measured by Mood Disorder Questionnaire
|
over the past year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Bipolar and Related Disorders
- Bipolar Disorder
- Suicide
- Suicidal Ideation
- Suicide, Attempted
- Self-Injurious Behavior
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- Antidepressive Agents
- Antimanic Agents
- Lithium Carbonate
Other Study ID Numbers
Other Study ID Numbers
- F2023-12-20-4-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.